首页> 美国卫生研究院文献>Molecular Therapy >Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical Developments
【2h】

Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical Developments

机译:电穿孔的DNA疫苗和免疫疗法的交付:当前的临床进展。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Electroporation (EP) has been used in basic research for the past 25 years to aid in the transfer of DNA into cells in vitro. EP in vivo enhances transfer of DNA vaccines and therapeutic plasmids to the skin, muscle, tumors, and other tissues resulting in high levels of expression, often with serological and clinical benefits. The recent interest in nonviral gene transfer as treatment options for a vast array of conditions has resulted in the refinement and optimization of EP technology. Current research has revealed that EP can be successfully used in many species, including humans. Clinical trials are currently under way. Herein, the transition of EP from basic science to clinical trials will be discussed.
机译:在过去的25年中,电穿孔(EP)已用于基础研究中,以帮助将DNA体外转移到细胞中。体内EP增强了DNA疫苗和治疗性质粒向皮肤,肌肉,肿瘤和其他组织的转移,从而导致高水平的表达,通常具有血清学和临床益处。对于将非病毒基因转移作为多种疾病的治疗选择的最新兴趣导致了EP技术的完善和优化。当前的研究表明,EP可以成功地用于包括人类在内的许多物种。目前正在进行临床试验。在此,将讨论EP从基础科学到临床试验的转变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号